arrow
M

Michele Potashman

biohaven pharmaceuticals inc
H指数:20
被引数:6,566

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Incorporating Patient Perspectives into a Composite Score for Measuring Disease Progression in Spinocerebellar Ataxia (SCA)

将患者视角纳入帕金森小脑共济失调(SCA)疾病进展测量中的复合评分

2026-02-180
OAAI
Development of Composite Scales for Assessing Disease Progression and Treatment Effects Among Patients with Parkinson’s Disease in a Clinical Trial Setting

在临床试验背景下,针对帕金森病患者疾病进展和治疗效应评估的复合量表开发

2025-10-100
PRE
Content Validity of the Spinocerebellar Ataxia Composite Score as a Measure of Disease Progression in Patients with Spinocerebellar Ataxia

脊髓小脑共济失调复合评分的内容效度:作为脊髓小脑共济失调患者疾病进展的测量指标

2025-09-010
OAAI
Content Validity of the Friedreich Ataxia Rating Scale in Patients with Spinocerebellar Ataxia

脊髓小脑性共济失调患者Friedreich共济失调评定量表的内容效度

2025-01-151
OAAI
Psychometric Validation of a Modified United Multiple System Atrophy Rating Scale

改良的联合多系统萎缩评分量表的心理测量验证

2023-04-250
PRE
Technical Review of Clinical Outcomes Assessments Across the Continuum of Alzheimer's Disease
2023-02-159
OAAI
Assessing What Matters to People Affected by Alzheimer's Disease: A Quantitative Analysis
2023-02-1013
OAAI
Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019

全球痴呆症2019年患病率的估计和预测患病率2050年: 全球疾病负担研究2019的分析

2022-02-01873
OA
Health-related quality of life in people with predementia Alzheimer's disease, mild cognitive impairment or dementia measured with preference-based instruments: a systematic literature review
2020-11-1852
OAAI